新华制药
(000756)
| 流通市值：67.87亿 | | | 总市值：102.78亿 |
| 流通股本：4.56亿 | | | 总股本：6.90亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,734,166,240.75 | 4,732,481,467.24 | 2,474,697,457.66 | 8,100,844,707.33 |
| 营业收入 | 6,734,166,240.75 | 4,732,481,467.24 | 2,474,697,457.66 | 8,100,844,707.33 |
| 二、营业总成本 | 6,337,089,365.67 | 4,414,193,942.13 | 2,328,929,009.3 | 7,530,904,783.94 |
| 营业成本 | 5,151,913,375.72 | 3,547,931,805.24 | 1,795,729,697.76 | 5,709,142,351 |
| 税金及附加 | 51,662,674.6 | 36,899,978.55 | 18,434,857.09 | 92,175,276.66 |
| 销售费用 | 504,223,794.96 | 403,565,129.41 | 291,064,033.27 | 780,171,394.31 |
| 管理费用 | 292,405,195.99 | 181,073,486.83 | 78,840,015.11 | 513,824,781.93 |
| 研发费用 | 326,669,940.69 | 243,105,634.2 | 141,905,763.44 | 419,239,700.9 |
| 财务费用 | 10,214,383.71 | 1,617,907.9 | 2,954,642.63 | 16,351,279.14 |
| 其中:利息费用 | 28,115,663.07 | 17,868,283.95 | 9,217,078.08 | 41,148,585.76 |
| 其中:利息收入 | 8,324,746.77 | 4,581,339.55 | 2,881,003.92 | 12,300,491.07 |
| 加:投资收益 | 8,399,571.55 | 9,516,606.83 | 1,188,728.16 | 9,583,372.02 |
| 资产处置收益 | 1,201,542.62 | 1,240,258.42 | 845,111.01 | 8,733,639.41 |
| 资产减值损失(新) | -48,313,538.64 | -48,313,538.64 | - | -69,282,694.12 |
| 信用减值损失(新) | -8,073,501.52 | -8,193,415.41 | 70,000 | -10,294,468.42 |
| 其他收益 | 47,979,403.05 | 35,032,548.75 | 22,684,697.21 | 25,902,239.33 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 398,270,352.14 | 307,569,985.06 | 170,556,984.74 | 534,582,011.61 |
| 加:营业外收入 | 659,426.07 | 326,560.85 | 193,820.84 | 5,537,126.16 |
| 减:营业外支出 | 6,012,150.78 | 4,532,708.22 | 1,979,283.56 | 7,433,412.75 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 392,917,627.43 | 303,363,837.69 | 168,771,522.02 | 532,685,725.02 |
| 减:所得税费用 | 37,468,356.21 | 30,597,489.83 | 23,507,423.62 | 26,578,700.01 |
| 六、净利润 | 355,449,271.22 | 272,766,347.86 | 145,264,098.4 | 506,107,025.01 |
| 持续经营净利润 | 355,449,271.22 | 272,766,347.86 | 145,264,098.4 | 506,107,025.01 |
| 归属于母公司股东的净利润 | 344,079,950.67 | 265,404,417.68 | 141,879,437.62 | 496,512,201.25 |
| 少数股东损益 | 11,369,320.55 | 7,361,930.18 | 3,384,660.78 | 9,594,823.76 |
| (一)基本每股收益 | 0.5 | 0.39 | 0.21 | 0.74 |
| (二)稀释每股收益 | 0.5 | 0.38 | 0.21 | 0.72 |
| 八、其他综合收益 | 74,961,072.66 | 27,326,906.39 | 815,327.77 | 1,736,014.71 |
| 归属于母公司股东的其他综合收益 | 75,223,458.18 | 27,600,823.6 | 807,373.6 | 1,491,268.41 |
| 九、综合收益总额 | 430,410,343.88 | 300,093,254.25 | 146,079,426.17 | 507,843,039.72 |
| 归属于母公司股东的综合收益总额 | 419,303,408.85 | 293,005,241.28 | 142,686,811.22 | 498,003,469.66 |
| 归属于少数股东的综合收益总额 | 11,106,935.03 | 7,088,012.97 | 3,392,614.95 | 9,839,570.06 |
| 公告日期 | 2024-10-30 | 2024-08-23 | 2024-04-26 | 2024-03-29 |
| 审计意见(境内) | | | | 标准无保留意见 |